27.10.2026 07:00:08 CET | Thor Medical ASA | Non-regulatory press releases

Thor Medical, a leading supplier of high-purity isotopes to the
radiopharmaceutical industry, has entered into a three-year supply agreement
with Medicines Discovery Catapult (MDC), a life science service dedicated to
turning drug discovery into commercial breakthroughs.

Under the agreement, Thor Medical will supply radium-224 (Ra-224) and lead-212
(Pb-212) from its industrial-scale AlphaOne facility. The agreement will support
MDC's wider work to accelerate the development of Pb-212- and Ra-224-based
radiopharmaceutical therapies in the UK. First shipments to MDC have already
been made.

"We are pleased to support Medicines Discovery Catapult with the isotopes it
needs to help advance radiopharmaceutical development in the UK. Since opening
AlphaOne, we are seeing increasing interest in securing predictable and stable
isotope supply, which is an important enabler for preclinical development. We
look forward to supporting MDC and the programmes it works with over the coming
years," said Jasper C. Kurth, CEO of Thor Medical.

With increasing investment in the development, manufacture, and clinical
translation of precision radiopharmaceutical medicines, a reliable supply of
medical isotopes remains fundamental to advancing research and development in
this space.

Alongside securing isotope supplies for development programmes, MDC is
supporting initiatives to strengthen the UK's future capability. This includes a
£18.8 million consortium, partially funded by Innovate UK's Sustainable
Medicines Manufacturing Innovation Programme and led by United Kingdom National
Nuclear Laboratory and Medicines Discovery Catapult, which is working to
establish the ecosystem of a UK Pb-212 supply chain.

Together, these activities help ensure innovators can access the isotopes they
need today while supporting the long-term growth of UK radiopharmaceutical
capability.

"This agreement with Thor Medical strengthens MDC's ability to support
radiopharmaceutical developers in getting precision treatments closer to
patients. By combining isotope supply with MDC's preclinical development
capabilities, we can help partners generate the evidence needed to progress
programmes from early discovery to clinical development and future impact," said
Dr. Juliana Maynard, Chief Scientist, Translational Imaging and
Radiopharmaceuticals, Medicines Discovery Catapult.

ENDS

For further information, please contact:

Thor Medical ASA

Mathias Nilsen Reierth

Head of Communications and Corporate Affairs

+47 988 05 724

mathias.reierth@thormedical.com

 

Medicines Discovery Catapult

Georgia Hawkins

Senior Communications Manager

media@md.catapult.org.uk - georgia.smith@md.catapult.org.uk

 

ABOUT THOR MEDICAL ASA

Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies.

Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor
isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally
occurring thorium, Thor Medical's production process requires neither
irradiation nor nuclear reactors, providing significant cost advantages while
minimizing radioactive waste.

Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by powering
the next generation of precision cancer treatment with high-purity isotopes.
Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED. For more information, visit 
thormedical.com - http://thormedical.com

 

ABOUT MEDICINES DISCOVERY CATAPULT

Medicines Discovery Catapult (MDC) is a Life Sciences service dedicated to
turning drug discovery into commercial breakthroughs.

At the frontier of drug discovery, MDC works with entrepreneurial scientists to
make every move count. It validates their ideas, de-risks investments, and feeds
insights back into the sector to drive productivity and impact.?

MDC creates momentum through its unique blend of discovery expertise,
technology, insights, and sector-leading partnerships. Where there is unmet
patient need, MDC stimulates innovation through its National Programmes. ?

MDC has worked with over 427 organisations, who have gone on to raise more than
£2.2bn of R&D investment.?

Its approach to drug discovery drives game-changing breakthroughs and improves
patients' lives.?

More information:

 * Part of the Innovate UK Catapult Network
 * Based in Alderley Park, Cheshire
 * For more information, visit https://md.catapult.org.uk/

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19118517/19603/Download%20announc
ement%20as%20PDF.pdf
rg.uk/\
\
ATTACHMENTS\
\
Download announcement as PDF.pdf -\
https://kommunikasjon.ntb.no/ir-files/17848634/19118517/19603/Download%20announc\
ement%20as%20PDF.pdf\